FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973

FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973

Bibliographic Details
Main Authors: Baudy, Andreas R, Dogan, Taner, Flores-Mercado, Judith E, Hoeflich, Klaus P, Su, Fei, van Bruggen, Nicholas, Williams, Simon-Peter
Format: Online
Language:English
Published: Springer 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405466/
id pubmed-3405466
recordtype oai_dc
spelling pubmed-34054662012-07-26 FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973 Baudy, Andreas R Dogan, Taner Flores-Mercado, Judith E Hoeflich, Klaus P Su, Fei van Bruggen, Nicholas Williams, Simon-Peter Original Research Springer 2012-05-31 /pmc/articles/PMC3405466/ /pubmed/22651703 http://dx.doi.org/10.1186/2191-219X-2-22 Text en Copyright ©2012 Baudy et al.; licensee Springer. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Baudy, Andreas R
Dogan, Taner
Flores-Mercado, Judith E
Hoeflich, Klaus P
Su, Fei
van Bruggen, Nicholas
Williams, Simon-Peter
spellingShingle Baudy, Andreas R
Dogan, Taner
Flores-Mercado, Judith E
Hoeflich, Klaus P
Su, Fei
van Bruggen, Nicholas
Williams, Simon-Peter
FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973
author_facet Baudy, Andreas R
Dogan, Taner
Flores-Mercado, Judith E
Hoeflich, Klaus P
Su, Fei
van Bruggen, Nicholas
Williams, Simon-Peter
author_sort Baudy, Andreas R
title FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973
title_short FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973
title_full FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973
title_fullStr FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973
title_full_unstemmed FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973
title_sort fdg-pet is a good biomarker of both early response and acquired resistance in brafv600 mutant melanomas treated with vemurafenib and the mek inhibitor gdc-0973
description
publisher Springer
publishDate 2012
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405466/
_version_ 1611545700344004608

Similar Items